治疗心力衰竭的empagliflozin与糖尿病和没有糖尿病的左心室喷射部分
Gerasimos Filippatos1, Javed Butler2,3, Dimitrios Farmakis4
1National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Greece (G.F.).
Circulation
|June 28, 2022
概括
无论糖尿病状况如何,恩帕格利弗洛辛对心力衰竭患者有好处. 这种SGLT2抑制剂在糖尿病和非糖尿病患者中持续减少心力衰竭住院和心血管死亡.
科学领域:
- 心脏病学
- 内分泌学
- 药理学
背景情况:
- 全球有数百万人患有心脏衰竭与保存的喷射分数 (HFpEF).
- 糖尿病是HFpEF患者常见的并发症.
- 在不同血糖状态下,SGLT2抑制剂对HFpEF的有效性需要澄清.
研究的目的:
- 调查empagliflozin对糖尿病患者和没有糖尿病患者的HFpEF结果的影响.
- 评估empagliflozin在血糖谱中的益处的一致性.
主要方法:
- 对EMPEROR-Preserved试验 (NCT03057951) 进行了预先规定的分析.
- 患有HFpEF (LVEF> 40%) 的患者接受了empagliflozin 10 mg或安慰剂.
- 分组分析基于基线糖尿病状况对比结果.
主要成果:
- 无论糖尿病状况如何,Empagliflozin显著降低了主要结局 (心血管疾病住院或心血管疾病死亡) (Pinteraction=0. 92).
- 在糖尿病和非糖尿病组中,对HF住院总数和eGFR下降的好处是一致的.
- 在empagliflozin组中没有观察到低血糖的风险增加.
结论:
- 无论患者的糖尿病状况如何,empagliflozin在减少心力衰竭事件方面表现一致.
- 这些发现支持使用empagliflozin作为广泛的HFpEF患者的治疗选择.
相关概念视频
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:23Dipeptidyl Peptidase 4 Inhibitors
248
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
248
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure Drugs: Diuretics
479
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
479
01:22Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
28
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
28